News
-
Oracle Health Sciences Institute, In Partnership With Oracle Labs, Announces First Round Of Research Projects
2/3/2012
Oracle Health Sciences Institute, in partnership with Oracle Labs, recently announced its first group of research projects, which includes initiatives with Brigham and Women’s Hospital and Harvard Medical School; the Coalition Against Major Diseases (CAMD) at the Critical Path Institute; the Human-Computer Interaction Lab (HCIL) at the University of Maryland.
-
NEJM Features Two Positive Pivotal Trials Of HRA Pharma Compound Ulipristal Acetate For The Treatment Of Uterine Fibroids
2/3/2012
The New England Journal of Medicine (NEJM) recently published results of two phase III clinical trials introducing ulipristal acetate, HRA Pharma proprietary compound, as an effective pre-operative treatment of symptoms of uterine fibroids.
-
Lubiprostone Meets Primary Endpoint In Phase 3 Clinical Trial For Opioid-Induced Bowel Dysfunction (OBD)
2/3/2012
Sucampo Pharmaceuticals, Inc. (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced recently that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
-
Ampio Pharmaceuticals, Inc. Announces Statistically Significant Improvement In Pain Relief For Its Lead Product, Ampion In The Osteoarthritis Of The Knee Trial
2/1/2012
Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced preliminary results of the pain score portion of the expansion phase of Ampion™ in Knee (AIK) trial which was recently completed in Australia.
-
Oracle Unveils Oracle Health Sciences Omics Data Bank As Part Of Oracle Health Sciences Translational Research Center
1/24/2012
Oracle Health Sciences recently announced availability of Oracle Health Sciences Omics Data Bank, a molecular data model, which is part of Oracle Health Sciences Translational Research Center.
-
NW Bio Reaches 25 Clinical Trial Sites Open And Recruiting By The End Of Q4, 2011
1/10/2012
Northwest Biotherapeutics (OTC.BB: NWBO) (NW Bio) today announced that it successfully met its projection that it would have 25 trial sites open and recruiting by the end of Q4, 2011, in its ongoing clinical trial of DCVax®; immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer.
-
HRA Pharma’s Partner, PregLem, The Wholly Owned Subsidiary Of Gedeon Richter Plc, Receives Positive CHMP Opinion For Uterine Fibroids Treatment
12/20/2011
HRA Pharma announces that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMA), has issued a positive opinion recommending a marketing authorization for Esmya (ulipristal acetate) for pre operative treatment (3months) of moderate to severe symptoms in patients with uterine fibroids.
-
Roche Announces Positive Results Of Pivotal Phase III Study With Pertuzumab In HER2-Positive Metastatic Breast Cancer
12/12/2011
Roche recently announced results from CLEOPATRA, the first randomised Phase III study of the investigational HER2-targeted medicine pertuzumab.
-
New Data Confirms Novartis Drug Afinitor Significantly Extends Time Women With Advanced Breast Cancer Live Without Tumor Growth
12/9/2011
The study findings, which represent an additional five months of follow-up, were presented at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), abstract #S3-7.
-
Generex Subsidiary Antigen Express To Present AE37 Cancer Vaccine Phase 2 Clinical Data At 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11/23/2011
Generex Biotechnology Corporation (OTCBB: GNBT.OB) (www.generex.com) announced today that its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will present new Phase 2 clinical data from its study of a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine (AE37) in HER-2 expressing breast cancer patients at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas on December 7, 2011.
This website uses cookies to ensure you get the best experience on our website. Learn more